CLEC10A and embryonal neoplasm: We observed the first evidence of HML-2 expression in the embryonal tumor, AT/RT, and we suggest that its expression may be (1) a useful diagnostic tool and biomarker for surveillance of progression or treatment response and (2) an excellent new therapeutic target.